Qiagen NV represents a strong dedication to innovation, collaboration, and integrity. With a focus on providing cutting-edge solutions for molecular diagnostics and life sciences research, Qiagen NV is committed to improving patient outcomes and advancing healthcare globally. The company's corporate philosophy centers around relentlessly pursuing scientific breakthroughs and enabling scientists and healthcare professionals to make impactful discoveries. By leveraging their expertise in nucleic acid sample preparation and analysis, Qiagen NV aims to empower researchers and clinicians in their quest for improved diagnostics and personalized medicine. Emphasizing excellence, Qiagen NV continues to drive innovation and contribute to the betterment of global health.

Qiagen NV is primarily present in various countries and regions globally. The company has a significant presence in the United States, Germany, the Netherlands, China, and Switzerland, among others. With its headquarters in Germany, Qiagen NV operates in over 35 countries, serving customers in diverse regions and markets. By focusing on innovative molecular testing solutions, Qiagen NV is committed to improving healthcare outcomes and enabling scientific advancements worldwide.

Qiagen NV has achieved numerous significant milestones throughout its history. Some of these notable achievements include the development of innovative molecular sample and assay technologies, which have revolutionized the field of life sciences. The company has consistently delivered solutions that enable researchers and scientists worldwide to make groundbreaking discoveries and advancements in genomics, proteomics, and cellular analysis. Qiagen NV has also expanded its global presence by establishing strategic collaborations and partnerships, enhancing its product portfolio, and consistently delivering strong financial performance. These achievements reflect Qiagen NV's dedication to innovation, scientific excellence, and commitment to addressing the evolving needs of its customers in the life sciences industry.

Qiagen NV is a leading global provider of sample and assay technologies in the field of molecular diagnostics, applied testing, and academic research. Founded in 1984, Qiagen has a rich history of developing innovative solutions for the life sciences industry. The company offers a broad range of products and services including sample preparation, DNA sequencing, and genetic testing. With a strong focus on molecular biology and bioinformatics, Qiagen has established itself as a trusted partner for researchers, healthcare professionals, and pharmaceutical companies worldwide. Over the years, Qiagen has consistently delivered high-quality products, driving advancements in genomics and personalized medicine.

The main competitors of Qiagen NV in the market are Thermo Fisher Scientific Inc., Illumina Inc., and Becton, Dickinson and Company.

Qiagen NV is primarily active in the biotechnology and life sciences industries.

The business model of Qiagen NV focuses on providing innovative solutions for molecular testing and diagnostics. Qiagen NV specializes in sample and assay technologies that enable researchers and healthcare professionals to extract, isolate, and purify nucleic acids from biological samples. They offer a comprehensive portfolio of products and services that cater to various applications, including insights into diseases, personalized healthcare, and forensic analysis. By leveraging their expertise in molecular biology and bioinformatics, Qiagen NV aims to contribute to the advancement of diagnostics, research, and precision medicine.

Rasio P/E Qiagen adalah 19,30.

Rasio KUV dari Qiagen adalah 4,50.

Skor Kualitas AlleAktien untuk Qiagen adalah 3/10.

Omset diharapkan Qiagen adalah 2,04 miliar USD.

Laba diharapkan Qiagen adalah 476,41 Juta. USD.

Qiagen NV is a biotechnology company based in the Netherlands that specializes in the production of medical and laboratory equipment. The company offers a wide range of products and services, including the discovery and validation of biomarkers, the isolation of DNA and RNA, and the performance of gene expression analysis. This article describes the business model of Qiagen NV, including its various divisions and products.

Qiagen membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Qiagen saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Qiagen adalah NL0012169213.

WKN dari Qiagen adalah A2DKCH.

Ticker dari Qiagen adalah QGEN.

Dalam 12 bulan terakhir, Qiagen membayar dividen sebesar 1,08 USD . Ini setara dengan yield dividen sekitar 2,63 %. Untuk 12 bulan mendatang, Qiagen diperkirakan akan membayar dividen sebesar 0 USD.

Imbal hasil dividen dari Qiagen saat ini adalah 2,63 %.

Qiagen membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan Februari, Februari, Februari, Februari.

Qiagen membayar dividen setiap tahun dalam 5 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

Qiagen dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Qiagen tanggal 1/2/2024 sejumlah 1,32 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 30/1/2024.

Pembayaran dividen terakhir dilakukan pada 1/2/2024.

Pada tahun 2023, Qiagen 0 USD telah dibayarkan sebagai dividen.

Dividen dari Qiagen dibayarkan dalam USD.